Role of TH17 in the pathogenesis of cutaneous inflammatory diseases

Journal of Biological Regulators and Homeostatic Agents

Volumn 26, Issue 3, 2012, Pages 313-318

  Chiricozzi, Andrea ^a,b   Zhang, S ^b,c   Dattola, A ^a   Gabellini, M ^a   Chimenti, S ^a   Nistico S P ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ROCKEFELLER UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allergic contact dermatitis; Atopic dermatitis; IL 17; Psoriasis; Th17

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; AIN 648; BRODALUMAB; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR6; GAMMA INTERFERON; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN E; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 19; INTERLEUKIN 22; INTERLEUKIN 23; IXEKIZUMAB; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; NICKEL; PLACEBO; RG 4934; SECUKINUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ASTHMA; ATOPIC DERMATITIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL INFILTRATION; CELL POPULATION; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DISEASE EXACERBATION; EOSINOPHILIA; GENE OVEREXPRESSION; HUMAN; HUMORAL IMMUNITY; HYPERKERATOSIS; IMMUNOPATHOGENESIS; INJECTION SITE ERYTHEMA; INNATE IMMUNITY; KIDNEY COLIC; LICHENOID ERUPTION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MICROSCOPY; MYELOID DENDRITIC CELL; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SUBUNIT; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SKIN ALLERGY; SKIN DEFECT; SKIN MANIFESTATION; TH1 CELL; TH1 TH2 BALANCE; TH17 CELL; TH2 CELL; UPPER RESPIRATORY TRACT INFECTION; UPREGULATION;

ANIMALS; DERMATITIS, ATOPIC; DERMATITIS, CONTACT; HUMANS; INFLAMMATION; INTERLEUKIN-17; PSORIASIS; TH17 CELLS;

EID: 84868157684     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997; 18(6):263-6. (Pubitemid 27261442)
2. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6(11):1123-32. (Pubitemid 41541790)
3. Rouvier E, Luciani MF, Mattei MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a Herpes virus Saimiri gene. J Immunol 1993; 150:5445-5456. (Pubitemid 23180658)
4. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, Kuchroo VK, Hafler DA. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008; 454(7202):350-2.
5. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucialrole for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 2006; 203(7):1685-91. (Pubitemid 44036274)
6. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278:1910-14. (Pubitemid 36801431)
7. Oppmann B, Lesley R, Blom B, et al. Novel p19 proteinen gages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13(5):715-25.
8. Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol 1999; 162:494-502. (Pubitemid 29018959)
9. Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I, Sekikawa K, Asano M, Iwakura Y. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002; 17(3):375-87.
10. He D, Wu L, Kim HK, Li H, Elmets CA, Xu H.CD8+ IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses. J Immunol 2006; 177(10):6852-8. (Pubitemid 44715050)
11. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, Bowman EP, Krueger JG. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128(5): 1207-11. (Pubitemid 351543220)
12. Ortega C, Fernández-A S, Carrillo JM, Romero P, Molina IJ, Moreno JC, Santamaria M. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th 17-related cytokines. J Leukoc Biol 2009; 86(2):435-43.
13. Caruso R, Botti E, Sarra M, et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009; 15(9):1013-5.
14. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, Dhodapkar M, Krueger JG. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199(1):125-30. (Pubitemid 38076484)
15. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006; 36(5):1309-23.
16. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 2005(5):273-9. (Pubitemid 41577417)
17. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, Nograles KE, Tian S, Cardinale I, Chimenti S, Krueger JG. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011; 131(3):677-87.
18. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006; 203(12):2577-87. (Pubitemid 44833335)
19. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665-74. (Pubitemid 351671883)
20. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012; 366(13):1181-9.
21. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366(13):1190-9.
22. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2(52):52ra72.
23. Papp KA, et al. 'Secukinumab efficacy and safety preliminary results from a phase II subcutaneous dose-ranging study in the treatment of moderate-to-severe plaque psoriasis.' Presented at: 20th Congress of the European Academy of Dermatology and Venereology; 20-24 October, 2011; Lisbon, Portugal. Oral presentation FC01.5.
24. Papp KA, et al. 'Secukinumab, a novel fully human antibody to interleukin-17A, in the treatment of moderate-to-severe plaque psoriasis: Efficacy and safety interim results from a phase II intravenous induction dose-ranging study.' Presented at: 20th Congress of the European Academy of Dermatology and Venereology; 20-24 October, 2011; Lisbon, Portugal. Oral presentation FC01.7.
25. Guttman-Yassky E, Suárez-Fariñas M, Chiricozzi A, et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol 2009; 124(6):1235-1244.
26. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest 2004; 113(5):651-7. (Pubitemid 38544154)
27. Nograles KE, Zaba LC, Shemer A, et al. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 2009; 123(6):1244-52.
28. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008; 223:87-113. (Pubitemid 351986173)
29. Al-Ramli W, Préfontaine D, Chouiali F, Martin JG, Olivenstein R, Lemière C, Hamid Q. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol 2009; 123(5):1185-7.
30. Molet S, Hamid Q, Davoine F, et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001; 108(3):430-8. (Pubitemid 32881066)
31. Laan M, Cui ZH, Hoshino H, Lötvall J, Sjöstrand M, Gruenert DC, Skoogh BE, Lindén A. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999; 162(4):2347-52. (Pubitemid 29288861)
32. Schnyder-Candrian S, Togbe D, Couillin I, et al. InterIeukin-17 is a negative regulator of established allergic asthma. J Exp Med 2006; 203(12):2715-25. (Pubitemid 44833347)
33. Toda M, Leung DY, Molet S, et al. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol 2003; 111(4):875-81. (Pubitemid 36470263)
34. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 2008; 128(11):2625-30.
35. Nakatani T, Kaburagi Y, Shimada Y, Inaoki M, Takehara K, Mukaida N, Sato S. CCR4 memory CD4+ T lymphocytes are increased in peripheral blood and lesional skin from patients with atopic dermatitis. J Allergy Clin Immunol 2001; 107(2):353-8. (Pubitemid 32173915)
36. Milovanovic M, Drozdenko G, Weise C, Babina M, Worm M. Interleukin-17A promotes IgE production in human B cells. J Invest Dermatol 2010; 130(11):2621-8.
37. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 2008; 181(10):7420-7.
38. Nograles KE, Suárez-Fariñas M, Shemer A, et al. Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses. J Allergy Clin Immunol 2010; 125(3):744-6, 746.e1-746.e2.
39. Ong PY, Leung DY. The chemokine receptor CCR6 identifies interferon-gamma expressing T cells and is decreased in atopic dermatitis as compared with psoriasis. J Invest Dermatol 2002; 119(6):1463-4. (Pubitemid 36005636)
40. Schmuth M, Neyer S, Rainer C, Grassegger A, Fritsch P, Romani N, Heufler C. Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier function. Exp Dermatol 2002; 11(2):135-42. (Pubitemid 36934631)